Patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis who received a novel ...

After 52 weeks of treatment, patients taking the highest two doses saw their liver fibrosis improve by 44% to 57%, compared ...

In normal liver, hepatic stellate cells (HSCs ... provide a framework for new concepts of diagnosis and treatment of hepatic fibrosis.

This treatment mediates long-term reversal of liver fibrosis and MASH, counteracts obesity, excessive fat accumulation, insulin resistance characteristic of type 2 diabetes, and the development of ...

Liver fibrosis is a progressive and potentially reversible condition that results from chronic liver damage, which can be ...

Learn about HMGB1's crucial role in liver diseases, its pathways and therapeutic potential that can treat liver diseases.

The Fibrosis-4 Index (FIB-4 ... formerly known as nonalcoholic fatty liver disease. Instead, lifestyle changes are the only ...

UAB researchers have reversed metabolic dysfunction-associated steatohepatitis (MASH) in mouse models. MASH is a severe liver disease associated with obesity and type 2 diabetes that affects more than ...

Carisma Therapeutics Inc. (CARM) presented promising preclinical data on engineered macrophages for treating liver fibrosis at the ...

Subset analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis in difficult-to-treat MASH patientsBoth artificial ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...